Adial Pharmaceuticals ADIL 深 沪
已收盘 11-07 16:00:00 美东时间
0.3256
-0.001
-0.43%
华盛通- 最 高0.3268
- 今 开0.321
- 成交量 24.97万股
- 最 低 0.313
- 昨 收 0.327
- 总市值 710.73万
- 52周最高 1.30
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.22
- 委 比 14.53%
- 总股本 2182.82万
- 历史最高 236.00
- 量 比 0.70
- 振 幅 4.22%
- 历史最低 0.22
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Adial Pharmaceuticals CEO Cary Claiborne appeared on the Emmy Award-winning Big Biz Show, which aired nationally on Fox Business, NBCUniversal, and Time Warner Cable, as well as globally on 175 countries via radio and streaming platforms. Adial is focused on developing treatments for addiction, with its lead drug AD04 showing promise in reducing alcohol consumption in heavy drinkers and potentially treating other addictive disorders like opioid u...
10-17 13:00
Adial Pharma Completes Analytical Validation Of Cheek Swab Collection Method For Testing Patients For Both Clinical Trial Usage As Well As Future Commercial Application
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today
10-09 20:40
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
Adial Pharmaceuticals announced the successful completion of analytical validation for a cheek swab collection method to test patients for AD04 development. This method identifies SNPs in the serotonergic system, enabling a patient-friendly companion diagnostic test for clinical trials and commercial use. The partnership with Genomind validated the assay for accuracy, reproducibility, and robustness, achieving 100% concordance. AD04 aims to treat...
10-09 12:30
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Maxim Group Upgrades Adial Pharmaceuticals to Buy, Announces $1.5 Price Target
Maxim Group analyst Jason McCarthy upgrades Adial Pharmaceuticals (NASDAQ:ADIL) from Hold to Buy and announces $1.5 price target.
09-30 20:32
Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder
Adial Pharmaceuticals received FDA backing for its Phase 3 AD04 trial, including endpoints and strategies for targeted populations in Alcohol Use Disorder treatment.
09-16 20:03
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
Adial Pharmaceuticals received positive FDA feedback on their Phase 3 clinical trial design for AD04 in treating Alcohol Use Disorder (AUD). FDA supported the adaptive trial design, biomarker stratification, and efficacy endpoints, including zero heavy drinking days in months 5 and 6. AD04 aims to target AG+ biomarker-positive patients, with plans for streamlined and rigorous Phase 3 development. The milestone strengthens Adial's position for reg...
09-16 12:00
Adial Pharma Receives 180-Day Nasdaq Extension To Regain Minimum Bid Price Compliance
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today
09-03 20:42
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
Adial Pharmaceuticals has been granted an additional 180 days until March 2, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The company must maintain a closing bid price of at least $1.00 for 10 consecutive business days during this period. Adial, focused on addiction treatments, recently tested its lead drug AD04 in a Phase 3 trial for Alcohol Use Disorder, showing promising results. The company will monitor its st...
09-03 12:30
Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments
<p>U.S. Senate support for expanding clinical trial endpoints beyond abstinence in substance use disorders validates Adial's patient-centric approach to AUD treatment. The new legislative measures, which passed with bipartisan support, encourage the FDA to adopt alternative endpoints such as reduced craving and alcohol use, aligning with Adial's strategy for AD04, a serotonin-3 receptor antagonist targeting AUD. CEO Cary Claiborne highlighted the...
08-20 12:30
